GE HealthCare
GEHC
$71.42
+3.49%
GE HealthCare Technologies is a leading medical technology company that develops, manufactures, and services medical imaging, ultrasound, advanced visualization, patient care, and pharmaceutical diagnostic solutions, operating within the Healthcare sector's Medical Devices industry. Spun off from General Electric in December 2022, the company holds leading market share in imaging and ultrasound equipment and is distinguished by an unusually high recurring-revenue base — roughly half of sales come from servicing, pharmaceutical diagnostics, and digital solutions — which gives it a more defensive, razor-and-blade profile than pure capital-equipment peers. The current investor narrative is dominated by a sharp reset in expectations: management cut 2026 earnings guidance in late April 2026 citing roughly $250 million of cost inflation that long sales cycles make difficult to offset quickly, driving a one-day collapse in the shares and a subsequent multi-month recovery debate. That debate now centers on whether the margin pressure is transitory and already priced in, versus a structural cost problem compounded by China exposure (about 11% of revenue) and tariff uncertainty, with bulls pointing to mid-single-digit revenue growth and a depressed forward multiple as the setup for a re-rating.…
GEHC
GE HealthCare
$71.42
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold with a constructive bias. The core thesis is that GEHC is a defensive, roughly half-recurring medtech franchise trading at 12.86x forward earnings — a 28.5% discount to its own 17.99x trailing multiple — where the market has already priced a margin scare that Q2 data suggests may be stabilizing, but where negative free cash flow and a PEG of 4.14 argue against chasing the stock before Q3 confirmation. The consensus 'buy' rating (mean 1.76 across 20 analysts) and average target of $82.70 (+18.9% upside) anchor the view that the risk/reward is skewed favorably, but the absence of any target below the current $69.57 also means the Street has no room to cut without moving below spot.
The supporting evidence is mixed but tilts positive on valuation and negative on cash. On the positive side: revenue grew 5.77% YoY to $5.295 billion in Q2 2026 with sequential acceleration from $4.674 billion in Q4 2025; gross margin recovered to 41.17% from 38.53% in Q1 2026; ROE is a healthy 20.08%; and the forward PE of 12.86x versus 17.99x trailing implies the market expects meaningful EPS growth into 2027. On the negative side: Q2 free cash flow was -$617 million, TTM FCF yield is only 2.4%, debt-to-equity is 0.964, and the PEG of 4.14 shows the growth is not cheap. Against the 18-22x typical of large-cap medtech peers, GEHC's 12.86x forward multiple is a 30-40% discount, but its 40.0% gross margin and 13.4% operating margin are also below premium peers, so part of the discount is structurally earned.
The biggest risks that could invalidate the thesis are a Q3 gross margin relapse below 40%, a second consecutive quarter of negative free cash flow, and any escalation in China/tariff exposure (roughly 11% of revenue). This Hold would upgrade to Buy if Q3 2026 confirms gross margin above 40% and free cash flow turns positive, or if the stock pulls back toward the $60-62 zone where the risk/reward improves materially; it would downgrade to Sell if gross margin falls below 38.5% (the Q1 2026 trough) or if consensus FY2026 EPS of $7.30 is cut. On balance the stock is fairly valued to modestly undervalued relative to its own history — the trailing PE of 17.99x sits mid-range versus 12.37x-50.01x since the spin-off — but not yet cheap enough to be a high-conviction buy before the margin question is answered.
Sign up to view all
GEHC 12-Month Price Forecast
The forward-looking view is balanced: valuation at 12.86x forward earnings and an analyst consensus target of $82.70 offer meaningful upside, and the Q2 gross margin recovery to 41.17% is genuine evidence the margin scare may be easing. But the -$617 million Q2 free cash flow, 2.4% TTM FCF yield, and PEG of 4.14 mean the earnings delivery embedded in the $7.30 consensus is not yet proven, and the concentration of Neutral ratings from Citigroup and JP Morgan shows the Street is waiting for confirmation. The base case (50% probability, $75-83) assumes margins stabilize in the low-40s and the stock grinds toward consensus, while the bear case (25%, $58.75-70) hinges on a Q3 margin relapse. I would upgrade to bullish if Q3 2026 shows gross margin above 41% with positive free cash flow, and downgrade to bearish if gross margin falls below 38.5% or consensus EPS is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $82.70 and implied upside of +15.8% versus the current price.
Average Target
$82.70
0 analysts
Implied Upside
+15.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $96
Analyst target range
Coverage is robust, with 20 analysts following GE HealthCare and a consensus recommendation of "buy" (mean rating of 1.76 on a 1-5 scale where 1 is strong buy). The average target price is $82.70, implying +18.9% upside from the current $69.57, and notably even the lowest target of $70.00 sits essentially at the current price — meaning the entire published range is at or above where the stock trades. Consensus estimates call for FY2026 EPS of $7.30 (range $7.19-$7.40) on revenue of $26.42 billion (range $26.12-$26.70 billion), which frames the bull case as a straightforward earnings-delivery story rather than a multiple-expansion story. The consensus leans clearly bullish, with the average target 18.9% above spot and no analyst publishing a target below the current price.
The target range of $70.00 to $96.00 is wide — a 37% spread from low to high — signaling meaningful disagreement about the margin trajectory. The $96 high target implies roughly 38% upside and would require both earnings delivery and multiple expansion toward the mid-teens forward PE, likely assuming cost inflation proves transitory and China/tariff headwinds fade. The $70 low target essentially prices in flat performance, consistent with a view that margin compression persists and the forward EPS estimate of $7.30 proves optimistic. Institutional ratings show a stable-to-improving pattern: BTIG reiterated Buy on September 17 and August 19, 2026; Evercore ISI and Wells Fargo maintained Outperform and Overweight respectively after Q2 results on July 30; UBS upgraded from Sell to Neutral on May 21, 2026 and has held Neutral since; Citigroup and JP Morgan remain Neutral. The absence of recent downgrades and the UBS upgrade off the lows suggest sentiment has bottomed, but the concentration of Neutral ratings from the bulge-bracket banks indicates the Street wants proof of margin stabilization before turning more constructive — a setup where Q3 results in late October are the key catalyst.
Drowning in data?
Find the real signal!
Bulls vs Bears: GEHC Investment Factors
The bear case currently has slightly stronger evidence on hard numbers — negative Q2 free cash flow of -$617 million, a PEG of 4.14, and a guidance cut that management itself attributed to cost inflation it cannot quickly offset — while the bull case rests more on valuation and sentiment inflections that are real but less proven. The bulls can point to a 12.86x forward PE, an analyst target range entirely above spot, and a Q2 gross margin recovery to 41.17% from 38.53%, but none of these yet demonstrate that the margin problem is solved. The single most important tension is whether the $250 million cost inflation is transitory or structural: if Q3 2026 gross margin holds above 40% and free cash flow turns positive, the 28.5% trailing-to-forward PE gap closes and the stock re-rates toward the $82.70 consensus; if margins roll over again, the discount is deserved and the $58.75 low comes back into play. Everything else — China, tariffs, the Neutral bulge-bracket stance — is secondary to that one margin question.
Bullish
- Forward PE of 12.9x is deeply discounted: GEHC trades at 12.86x forward earnings versus 17.99x trailing, a 28.5% discount that implies the market is pricing the Q1 2026 margin trough as permanent. On consensus FY2026 EPS of $7.30, the stock is at roughly 9.5x forward earnings, well below the 18-22x typical of large-cap medtech peers like Medtronic and Boston Scientific.
- Entire analyst target range above spot: With 20 analysts covering and a consensus 'buy' rating (mean 1.76), the average target of $82.70 implies +18.9% upside, and even the lowest published target of $70.00 sits above the current $69.57. No analyst has a target below the current price, a rare configuration that suggests downside is viewed as limited by the professional community.
- Recurring revenue base cushions cyclicality: Roughly half of sales are recurring — servicing (~one-third of revenue), pharmaceutical diagnostics (~10-15%), and digital solutions (~5%) — giving GEHC a razor-and-blade profile unusual among capital-equipment peers. Q2 2026 revenue of $5.295 billion grew 5.77% YoY, with PDx contributing $843 million of the total.
- Momentum has inflected off the lows: The stock is up 9.58% over one month and 10.31% over three months versus SPY's +1.22% and +2.69%, producing relative strength of +8.36 and +7.62 percentage points. At $69.57 the shares sit 34.9% up from the $58.75 low, indicating the April 2026 guidance-cut selling has been absorbed.
Bearish
- Negative free cash flow undermines the story: Q2 2026 operating cash flow was -$517 million and free cash flow -$617 million, a sharp reversal from Q2 2025's +$94 million and +$8 million. TTM FCF of $895 million against a $37.4 billion market cap yields just 2.4%, thin for a company carrying 0.964 debt-to-equity.
- Guidance cut signals structural cost problem: Management cut 2026 earnings guidance in late April 2026 citing roughly $250 million of cost inflation that long sales cycles make difficult to offset quickly, triggering a one-day collapse from $68.50 to $59.49 (-13.2%). The stock is still down 16.00% YTD and 5.19% over one year versus SPY's +11.93% and +15.53%.
- PEG of 4.14 flags expensive growth: Despite the low headline PE, the PEG ratio of 4.14 indicates the growth embedded in forward estimates is not cheap relative to the earnings trajectory. Consensus FY2026 EPS of $7.30 requires a strong second half that depends on working-capital release the first half did not deliver.
- China and tariff exposure cap the multiple: China represents about 11% of revenue and sits alongside tariff uncertainty, a structural overhang that helps explain the 30-40% forward PE discount to premium medtech peers. The 40.0% gross margin and 13.4% operating margin are also below the high-teens-to-mid-20s operating margins of premium peers, so part of the discount is earned.
GEHC Technical Analysis
GE HealthCare is in a recovery phase within a broader downtrend: the stock is down 5.19% over the past year and 16.00% year-to-date, badly lagging the S&P 500's +15.53% and +11.93% respective returns, with a maximum drawdown of -32.53% over the period. At $69.57, the shares sit at roughly 34.9% of the 52-week range of $58.75 to $89.77 — closer to the low than the high, but well off the bottom, meaning the stock has already absorbed the worst of the selling and is now in a repair phase rather than a freefall. The 52-week high of $89.77 remains 29.0% above the current price, underscoring how much ground would need to be reclaimed to restore the prior trend.
Short-term momentum has turned decisively positive and is diverging from the weak long-term trend. The stock is up 9.58% over the past month and 10.31% over three months, versus just +1.22% and +2.69% for SPY, producing relative strength of +8.36 and +7.62 percentage points over those windows — a clear sign of money rotating back into the name. That said, the six-month change of -6.82% and relative strength of -14.30 over that period show the recovery is recent and incomplete, and the -1.11% pullback on the latest session (from $70.35 to $69.57) on volume of about 3.12 million shares suggests the rally is meeting supply near $70. The pattern — strong 1-month and 3-month gains against a negative 1-year and YTD trend — is characteristic of mean-reversion off an oversold base rather than a confirmed new uptrend.
Key technical levels are well defined. Support sits at the 52-week low of $58.75, which was tested in late April 2026 after the guidance cut and again approached in the low-$60s through the summer; a breakdown below that zone would signal the market is re-pricing the margin story as structural and open the door to new lows. Resistance is the 52-week high of $89.77, with intermediate supply around the $74-75 area where the stock stalled in August 2026; a decisive breakout above $75 on volume would confirm the double-bottom recovery and put the $80s in play. With a beta of 0.848, the stock is roughly 15% less volatile than the market, which argues for somewhat larger position sizing on a risk-adjusted basis but also means it will likely lag in a sharp broad rally — a profile consistent with a defensive medtech name working through an idiosyncratic earnings reset.
Beta
0.85
0.85x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-6.2%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +7.8% | -1.2% |
| 3m | +17.9% | +3.4% |
| 6m | +3.8% | +7.0% |
| 1y | -6.2% | +14.4% |
| ytd | -13.8% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue is growing at a modest but stable pace. Q2 2026 revenue came in at $5.295 billion, up 5.77% year-over-year from $5.006 billion in Q2 2025, and the trailing four quarters total roughly $20.4 billion. The multi-quarter trend shows sequential progression from $4.674 billion in Q4 2025 to $5.131 billion in Q1 2026 to $5.295 billion in Q2 2026, with the year-over-year comparison improving from the Q4 2025 level of $5.319 billion (which was actually down versus Q4 2024's $5.319 billion) — so growth has re-accelerated modestly through the first half. Segment data for the latest period shows Advanced Imaging Solutions (AIS) at $3.771 billion, Pharmaceutical Diagnostics (PDx) at $843 million, Patient Care Solutions (PCS) at $675 million, and Other at $6 million, confirming imaging remains the dominant growth engine while the recurring PDx and service streams provide ballast. The 5.77% growth rate is respectable for a mature capital-equipment franchise but not enough to offset cost inflation on its own, which is precisely the crux of the guidance cut.
Profitability is solid in absolute terms but has been compressing. Q2 2026 net income was $573 million on a 10.82% net margin, with gross margin of 41.17% and operating margin of 13.96% — down from Q2 2025's 39.65% gross margin and 13.06% operating margin, and well below Q1 2025's 42.12% gross margin. The quarterly progression is telling: gross margin fell from 42.12% in Q1 2025 to 38.69% in Q3 2025, 38.53% in Q1 2026, before recovering to 41.17% in Q2 2026, while net margin swung from 11.81% in Q1 2025 to 7.58% in Q1 2026 and back to 10.82% in Q2 2026. The Q4 2025 quarter was an outlier with a 54.30% gross margin but only 3.94% net margin, distorted by $462 million of other expenses. The company remains comfortably profitable — trailing EPS of $0.056 on a per-share basis reflects a near-breakeven TTM figure distorted by the weak Q4, but the quarterly EPS run-rate of $1.24 in Q2 2026 annualizes to roughly $4.50-5.00, and consensus FY2026 EPS of $7.30 implies the market expects a strong second half. The margin trajectory is the single most important fundamental variable: stabilization above 40% gross margin would validate the bull case, while another leg down would confirm the cost problem is structural.
Balance sheet and cash flow present the most nuanced picture. Debt-to-equity stands at 0.964, current ratio at 1.175, and ROE at a healthy 20.08% (though this is flattered by a 3.39x equity multiplier and a low book base post-spin). The cash flow story is the weak spot: Q2 2026 operating cash flow was -$517 million and free cash flow was -$617 million, a sharp deterioration from Q2 2025's +$94 million operating and +$8 million free cash flow, driven by a $1.238 billion other-non-cash swing and working capital drag. TTM free cash flow is $895 million, which against a $37.4 billion market cap implies an FCF yield of just 2.4% — thin for a company with this debt load. Cash fell from $2.288 billion at the start of Q2 to $1.248 billion at quarter-end, and the company spent $200 million on buybacks and $100 million on capex during the quarter. The company can fund itself, but the negative first-half cash conversion means it is leaning on the balance sheet and will need a strong H2 working-capital release to hit full-year cash targets — a genuine risk factor that the headline EPS numbers obscure.
Quarterly Revenue
$5.3B
2026-06
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
41.2%
Latest Quarter
Free Cash Flow
$895000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Because GE HealthCare is profitable (Q2 2026 net income of $573 million, TTM net margin of 10.10%), the PE ratio is the appropriate primary metric. The stock trades at 17.99x trailing earnings but only 12.86x forward earnings — a 28.5% discount — which is a wide gap that implies the market expects meaningful EPS growth into 2027. That expectation is corroborated by consensus FY2026 EPS of $7.30 against the current $69.57 price, which works out to roughly 9.5x forward earnings on the analyst estimate, suggesting the trailing PE is depressed by one-off items (the weak Q4 2025 and the Q1 2026 margin trough) rather than reflecting the underlying earnings power. The PEG ratio of 4.14, however, warns that the growth embedded in that forward number is not cheap relative to the earnings trajectory.
Against the Medical Devices sector, the valuation looks inexpensive on earnings but rich on sales. The PS ratio of 1.82x and EV/Sales of 1.90x are low in absolute terms for a medtech franchise with leading imaging share, but the EV/EBITDA of 11.34x and P/B of 3.61x sit in a more normal range for the group. The forward PE of 12.86x is a clear discount to the roughly 18-22x typically commanded by large-cap medical device peers such as Medtronic or Boston Scientific, a spread of 30-40%, which the market is justifying with GEHC's lower growth (5.77% revenue growth), margin compression, and China/tariff exposure. The 40.0% gross margin and 13.4% operating margin are also below the high-teens-to-mid-20s operating margins of premium medtech peers, so part of the discount is structurally earned rather than an anomaly. The bull case rests on the gap closing as cost inflation normalizes; the bear case is that the discount is deserved.
Historically, GEHC has traded in a wide PE band since its 2022 spin-off. The trailing PE of 17.99x compares with 12.91x in Q2 2026, 20.94x in Q1 2026, 50.01x in Q4 2025 (distorted by the earnings trough), 19.16x in Q3 2025, and 12.37x in Q4 2024 — so the current multiple sits in the middle of its own range, neither stretched nor deeply discounted. The PS ratio of 1.82x, however, is near the low end of its historical band, which has ranged from roughly 5.4x to 8.8x on the reported quarterly series, though that series appears to use different share-count conventions and should be treated directionally. The P/B of 3.61x is below the 4.0-5.5x levels seen through 2023-2024, consistent with the de-rating. Net-net, the stock is not at a historical extreme — it is priced for a modest recovery, not a heroic one, which limits downside but also caps near-term multiple expansion without evidence of margin stabilization.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on cash generation and leverage. Q2 2026 operating cash flow was -$517 million and free cash flow -$617 million, a dramatic deterioration from the prior year's +$94 million and +$8 million, driven by a $1.238 billion other-non-cash swing and working-capital drag; cash fell from $2.288 billion to $1.248 billion during the quarter even as the company spent $200 million on buybacks and $100 million on capex. Debt-to-equity of 0.964 and a current ratio of 1.175 leave limited cushion, and TTM FCF of $895 million against a $37.4 billion market cap is a 2.4% yield that must improve in H2 for full-year cash targets to be met. Revenue concentration adds to the risk: Advanced Imaging Solutions alone was $3.771 billion of Q2's $5.295 billion, so any imaging capex slowdown hits the core directly, and the 5.77% growth rate is too modest to absorb cost inflation on its own.
Market and competitive risks are dominated by valuation compression and external exposure. The forward PE of 12.86x already embeds a 30-40% discount to premium medtech peers, but the PEG of 4.14 shows that if FY2026 EPS of $7.30 proves optimistic, the multiple has further to fall; the trailing PE has ranged from 12.37x to 50.01x since the 2022 spin-off, so the current 17.99x is mid-range rather than a floor. China at roughly 11% of revenue plus tariff uncertainty is a persistent overhang that management cannot control, and the stock's beta of 0.848 means it will lag in a sharp broad rally even as it cushions drawdowns. Competitive pressure is also visible in the sector: RadNet's $270 million Gleamer acquisition (March 2026) signals AI-driven diagnostic automation is attracting capital, and GEHC must defend imaging share against better-capitalized or more agile rivals while its own R&D spend of $323 million in Q2 is only 6.1% of revenue.
The worst-case scenario is a specific chain: Q3 2026 results in late October show gross margin falling back below 40% and free cash flow still negative, confirming the $250 million cost inflation is structural rather than transitory. That would force consensus FY2026 EPS of $7.30 lower, prompt the Neutral bulge-bracket banks (Citigroup, JP Morgan) to cut targets, and re-test the April 2026 panic low. From the current $69.57, a move to the 52-week low of $58.75 represents a loss of roughly -15.6%, and the maximum drawdown over the past year was already -32.53%, so a retest of the low plus slippage toward the $55 area would be a -20% to -21% outcome. The $70.00 low analyst target offers no downside cushion since it sits essentially at spot, meaning the published range provides no floor if the margin thesis breaks.
FAQ
The most severe risk is a margin relapse: if Q3 2026 gross margin falls back below the 38.5% Q1 2026 trough, the $250 million cost inflation is confirmed structural and consensus FY2026 EPS of $7.30 gets cut, potentially driving the stock toward the $58.75 low (-15.6%). Second is the cash-flow risk — Q2 2026 free cash flow was -$617 million with TTM FCF yield of just 2.4% against 0.964 debt-to-equity, so a second negative quarter would strain the balance sheet and the buyback. Third is geographic concentration, with China at roughly 11% of revenue exposed to tariff and policy uncertainty that management cannot control. Fourth is competitive and valuation risk: RadNet's $270 million Gleamer acquisition signals AI diagnostics competition intensifying, while the PEG of 4.14 means any growth disappointment compresses the multiple quickly.
The 12-month outlook has three scenarios: a base case (50% probability) targeting $75-83 as margins stabilize in the low-40s and the stock grinds toward the $82.70 consensus; a bull case (25%) targeting $89.77-96 if cost inflation proves transitory and the forward multiple re-rates toward the mid-teens; and a bear case (25%) targeting $58.75-70 if Q3 gross margin falls below 40% and free cash flow stays negative. The base case is most likely because it requires only that Q2's 41.17% gross margin holds and FY2026 EPS of $7.30 is met, both of which are consistent with the sequential revenue acceleration from $4.674 billion in Q4 2025 to $5.295 billion in Q2 2026. The key assumption is that the $250 million cost inflation is transitory; if that fails, the bear case dominates.
GEHC looks modestly undervalued on earnings but only fairly valued on cash flow. The trailing PE of 17.99x sits mid-range versus its post-spin history of 12.37x to 50.01x, while the forward PE of 12.86x represents a 28.5% discount to trailing and a 30-40% discount to the 18-22x typical of large-cap medtech peers like Medtronic and Boston Scientific. The PS ratio of 1.82x and EV/Sales of 1.90x are low in absolute terms for a franchise with leading imaging share, though the 40.0% gross margin and 13.4% operating margin are below premium peers, so part of the discount is structurally earned. The market appears to be pricing in a modest recovery, not a heroic one — the 12.86x forward multiple implies the market expects FY2026 EPS of $7.30 to be met but does not yet credit a full margin normalization. If Q3 confirms margin stabilization, the gap to peer multiples could close and the stock would look clearly cheap in hindsight.
From a risk/reward perspective, GEHC offers roughly +18.9% upside to the $82.70 average analyst target against a downside of about -15.6% to the $58.75 52-week low, a favorable ratio for a stock with a 0.848 beta. The valuation is undemanding at 12.86x forward earnings versus 17.99x trailing, and the entire $70-$96 analyst target range sits at or above the current $69.57, meaning no professional sees further downside. However, the -$617 million Q2 2026 free cash flow and 4.14 PEG mean the earnings delivery is unproven, and the Neutral stance of Citigroup and JP Morgan signals the Street wants Q3 confirmation first. It is a good buy for patient, risk-tolerant investors with a 12-18 month horizon who can tolerate a retest of the low-$60s, but conservative investors should wait for Q3 gross margin above 40% and positive free cash flow before committing.
GEHC is better suited to a medium-to-long-term holding than short-term trading. It is a mature, post-spin company (listed December 2022) with 5.77% revenue growth, a 0.17% dividend yield, and a beta of 0.848, meaning it lacks the volatility and momentum that short-term traders need — the stock's -32.53% maximum drawdown and 16.00% YTD decline show that timing entries poorly can be costly. Earnings visibility is moderate: consensus FY2026 EPS of $7.30 has a tight range of $7.19-$7.40, but the negative Q2 free cash flow introduces quarterly noise that makes short-term positioning risky. A suggested minimum holding period is 12-18 months, long enough to capture the Q3/Q4 2026 margin confirmation and the subsequent re-rating toward the $82.70 consensus target, while the defensive, half-recurring revenue base and 0.848 beta make it a reasonable long-term healthcare allocation.